This guideline covers managing stable angina in people aged 18 and over. It outlines the importance of addressing the person’s concerns about stable angina and the roles of medical therapy and revascularisation.
This guideline is restricted to GI endoscopy but we cover elective and acute or emergency procedures.
Abiomed, Inc. announced that it has received FDA Pre-Market Approval (PMA) for the Impella 2.5 heart pump during elective and...
The Medicines Company announced the approval of Kengreal (cangrelor) by the FDA as an adjunctive therapy to percutaneous coronary intervention...
Background: The optimal antithrombotic treatment after percutaneous coronary intervention (PCI) with stenting in patients with atrial fibrillation (AF) is unknown. In the ENGAGE AF-TIMI 48 trial, edoxaban was noninferior to...
Abiomed has expanded its FDA pre-market approval (PMA) for Impella heart pump use in high-risk percutaneous coronary interventions (PCI) to...
Ultrasound, if carried out correctly in the appropriate clinical situation, is one of the most effective diagnostic tools in healthcare....
This guideline, relating to the provision of a percutaneously placed enteral tube feeding service, is focused upon a specific area of nutrition provision that has not been previously targeted.
Abiomed announced that it has received an expanded FDA Pre-Market Approval (PMA) for the Impella 2.5 and Impella CP heart...
Aims: There is a paucity of evidence supporting routine beta blocker (BB) use in patients undergoing percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS). The aim of this study was to evaluate BB use post PCI and its association with mortality.